Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis
Pediatric Dermatology · 2026
DOI: 10.1111/pde.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Grace Eleanor Sessler Bruess und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical College of Wisconsin, Milwaukee, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Vaccines, Attenuated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Wisconsin Medical Society Foundation.
Abstract (Originalsprache)
Dupilumab is an IL‐4R α and IL‐13 inhibitor FDA‐approved for the treatment of atopic dermatitis (AD) in patients 6 months and older. Guidelines recommend against live‐attenuated vaccines due to limited safety data. We conducted a retrospective chart review of 233 patients aged 6 months to 10 years receiving dupilumab for AD at Children's Wisconsin, which showed that 19 received live vaccines during the study period. Four patients reported adverse events, including one requiring hospitalization. This study aims to evaluate the effects of live vaccines in children on dupilumab therapy and to assess associated adverse events, including in patients receiving their primary series of vaccines, a setting not previously described.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Medical College of Wisconsin, Milwaukee, USA.
- Division of Bioinformatics and Quantitative Child Health, Medical College of Wisconsin, Milwaukee, USA.
ORCID-Profile: Grace Eleanor Sessler Bruess, Kelly K Barry, Gerilyn M Olsen
Förderung
- Wisconsin Medical Society Foundation
Zitieren
APA
Bruess, G. E. S., Barry, K. K., Olsen, G. M., Foschi, C. M., Cook, E., Liegl, M., Pan, A. Y., & Lalor, L. (2026). Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. Pediatric Dermatology. https://doi.org/10.1111/pde.70033
Vancouver
Bruess GES, Barry KK, Olsen GM, Foschi CM, Cook E, Liegl M, et al. Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. Pediatric Dermatology. 2026. doi:10.1111/pde.70033
BibTeX
@article{Bruess2026,
author = {Bruess, Grace Eleanor Sessler and Barry, Kelly K and Olsen, Gerilyn M and Foschi, Cristina M and Cook, Elizabeth and Liegl, Melodee and Pan, Amy Y and Lalor, Leah},
title = {Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70033}
}
EUVIMED